NKGen Biotech, Inc. Common Stock (NKGN) 10-Q2024 Q1 Quarterly report

Filed: 20 May 24, 4:55pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Bad

New words: accredited, bridge, Brownian, ceiling, copy, coupon, covenant, disaggregated, duly, emanating, floor, fourth, furnish, Furnished, Geometric, herewith, hypothetical, implicit, investor, ix, language, lien, Motion, node, noncancelable, nonrecurring, NTD, path, point, Recoverability, recoverable, remeasurement, reset, rolling, ROU, shortfall, standalone, strike, subordinate, subscribe, synthetic, thereunto, trailing, Tree, unchanged, undersigned, VWAP, weekly, Winston

Removed: acting, approve, arbitration, audit, aware, Biden, blank, broad, capacity, care, Charter, check, chief, claim, close, committee, conducted, consumer, controlling, country, coverage, decide, deem, Department, description, detected, diligence, disclose, domestic, economy, enforceable, enhancing, entering, entirety, excluding, execute, exemption, exist, existed, extension, failed, favor, final, forfeit, generating, good, government, governmental, identification, implementation, implemented, imposed, imposition, improve, indemnification, inflation, instituted, institution, insurance, intended, interpretation, interpreted, introduce, invest, invested, issuable, jointly, law, liable, literature, litigation, longer, maintained, measuring, Medicare, military, mitigate, national, notice, offer, offered, opportunity, organized, permanent, person, President, priority, proceed, promptly, published, qualified, qualifying, receiving, reform, register, reimbursed, relying, remediation, rendered, requiring, resale, resolved, restriction, review, scheme, significantly, social, strategy, Street, suitable, sustained, system, target, team, temporary, tender, thereon, thereto, trade, training, Ukraine, utilized, valid, waive, Wall, whichever, winding, world, written

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

NKGN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATIONS

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Paul Y. Song, Chief Executive Officer of NKGen Biotech, Inc. (the “Company”), and James A. Graf, Interim Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

1.The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2024, to which this Certification is attached as Exhibit 32.1 (the “Quarterly Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2.The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

In Witness Whereof, the undersigned have set their hands hereto as of the 20th day of May, 2024.

/s/ Paul Y. Song

/s/ James A. Graf

Paul Y. Song

James A. Graf

Chief Executive Officer

Interim Chief Financial Officer